Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William F Hoffman

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Bioorganic & Medicinal Chemistry Letters|September 10, 2002
Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitorsMark E Fraley, William F Hoffman, Robert S Rubino, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinaseMark T Bilodeau, Leonard D Rodman, Georgia B McGaughey, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2003
Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG bindingMark E Fraley, Kenneth L Arrington, Carolyn A Buser, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2002
Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokineticsMark E Fraley, Robert S Rubino, William F Hoffman, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitorsMark E Fraley, Kenneth L Arrington, Scott R Hambaugh, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPMark E Fraley, Robert M Garbaccio, Kenneth L Arrington, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Bioorganic & Medicinal Chemistry Letters|September 10, 2002
Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitorsMark E Fraley, William F Hoffman, Robert S Rubino, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinaseMark T Bilodeau, Leonard D Rodman, Georgia B McGaughey, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2003
Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG bindingMark E Fraley, Kenneth L Arrington, Carolyn A Buser, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2002
Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokineticsMark E Fraley, Robert S Rubino, William F Hoffman, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitorsMark E Fraley, Kenneth L Arrington, Scott R Hambaugh, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPMark E Fraley, Robert M Garbaccio, Kenneth L Arrington, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Pageof 3